fbpx

scPharmaceuticals to Present at the Leerink Global Healthcare Conference

LEXINGTON, Mass. /PRNewswire/ – scPharmaceuticals, Inc., a privately held biopharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, announced today that Pieter Muntendam, President, CEO and founder of scPharmaceuticals, will present at Leerink Global Healthcare Conference in New York, NY on February 11, 2015.

Dr. Muntendam will provide an update on the company beginning at 11:30 a.m., Eastern Standard Time. About scPharmaceuticals: scPharmaceuticals, based in Lexington, MA, is a privately held biopharmaceutical company developing a portfolio of transformative pharmaceutical products for subcutaneous delivery. Based on widely used generic drugs that currently require intravenous or intramuscular injections, our innovative products will be administered subcutaneously via a proprietary patch pump.  This avoids material risks and costs associated with the current delivery options.  Our lead products are the first subcutaneous formulations of furosemide (the most widely used parenteral diuretic in treating heart failure) and ceftriaxone (the most widely used parenteral antibiotic outside the hospital setting).  Our novel furosemide formulation enables convenient anytime anywhere use, for example in an outpatient setting instead of the emergency room or other in-patient settings.  For ceftriaxone and other antibiotics, subcutaneous administration eliminates the need for PICCs (peripherally inserted central catheters), which are associated with serious complications, frequent adverse events and high medical cost.  For further information on how we are transforming the administration of parenteral drugs, go to www.scpharmaceuticals.com.

About scPharmaceuticals:
scPharmaceuticals, based in Lexington, MA, is privately held biopharmaceutical company developing a portfolio of transformative pharmaceutical products for subcutaneous delivery. The initial products are based on widely used generic drugs which now require intravenous or intramuscular injections.  scPharmaceuticals’ innovative products are administered using its proprietary patch pump device based on the revolutionary Swiss SenseCore technology. This breakthrough delivery system enables convenient and comfortable anytime anywhere administration of parenteral pharmaceuticals without the need for a healthcare professional to prepare and administer the medication. The scPharmaceuticals antibiotic products aim to avoid the use of PIC (Peripherally-Inserted Central) lines and associated risks, discomfort and costs. The scPharmaceuticals heart failure product aims to reduce utilization of emergency room and in-patient hospital services.

For More Information:

Katherine Taudvin
Director, Corporate Development
Email: ktaudvin@scpharma.com
Telephone: (781) 301-6706

News

90 million to 18 Talented Researchers
19. October 2020
Søren Dinesen Lumdbeckfonden
Psychiatry research leads to prestigious science prize
13. October 2020
Christian Sandøe Musaeus Lundbeckfonden
Concentrating on Dementia
13. October 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge